

Signal-Free Cancers

The lack of progress across today's killer cancers is not for want of trying. Nor has pharma lost appetite.

Pharma's investment follows the science. Specifically, pharma invests increasingly when drugs are tested in humans and signal is found. Unfortunately, despite testing many drug candidates, pharma has failed to find much signal across these cancers.

This failure holds back investment, which limits progress.

Data from April 2020

Cancer	Trials per Fatal Case, Normalised	Recruiting Industry Trials in the US
brain	0.18	53
oesophageal	0.21	47
colorectal	0.26	139
lung	0.30	352
liver	0.49	71
pancreatic	0.51	136
kidney	0.55	94
prostate	0.56	164
bladder	0.59	91
stomach	0.63	94
breast	0.97	328
ovary	1.0	132